Search research articles
Contact Us
Filters
Showing results (81-90 of 95) with videos related to
Page
of 10
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 29, 2017
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer
Chao Li, Cheng Huang, Tony S Mok, et al.
Journal of Neuro-Oncology
|
November 23, 2023
Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis
Yaping Hong, Qian Miao, Xinlong Zheng, et al.
Thoracic Cancer
|
June 8, 2025
Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer
Gen Lin, Yongsheng Wang, Tao Xin, et al.
Cancer Letters
|
July 3, 2026
Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer
Sixuan Wu, Senyuan Li, Yaqin Zheng, et al.
British Journal of Cancer
|
June 20, 2024
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
Paola Roa, Valentina Foglizzo, Guilherme Harada, et al.
Therapeutic Advances in Medical Oncology
|
October 1, 2025
Epidemiology and clinical characteristics of mesothelioma in the Chinese population: a multicenter study
Shengjie Yang, Yue Hao, Ke Wang, et al.
Frontiers in Immunology
|
November 28, 2022
CD8<sup>+</sup> T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types
Xinlong Zheng, Kan Jiang, Weijin Xiao, et al.
Lancet (London, England)
|
January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
Shun Lu, Jie Wang, Nong Yang, et al.
Journal of Medicinal Chemistry
|
May 2, 2024
Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2
Yunhang Guo, Hai Xue, Nan Hu, et al.
Journal of Medicinal Chemistry
|
August 6, 2019
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo, Ye Liu, Nan Hu, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 95) with videos related to
Sort By:
Page
of 10
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 29, 2017
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer
Chao Li, Cheng Huang, Tony S Mok, et al.
Journal of Neuro-Oncology
|
November 23, 2023
Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis
Yaping Hong, Qian Miao, Xinlong Zheng, et al.
Thoracic Cancer
|
June 8, 2025
Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer
Gen Lin, Yongsheng Wang, Tao Xin, et al.
Cancer Letters
|
July 3, 2026
Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer
Sixuan Wu, Senyuan Li, Yaqin Zheng, et al.
British Journal of Cancer
|
June 20, 2024
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
Paola Roa, Valentina Foglizzo, Guilherme Harada, et al.
Therapeutic Advances in Medical Oncology
|
October 1, 2025
Epidemiology and clinical characteristics of mesothelioma in the Chinese population: a multicenter study
Shengjie Yang, Yue Hao, Ke Wang, et al.
Frontiers in Immunology
|
November 28, 2022
CD8<sup>+</sup> T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types
Xinlong Zheng, Kan Jiang, Weijin Xiao, et al.
Lancet (London, England)
|
January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
Shun Lu, Jie Wang, Nong Yang, et al.
Journal of Medicinal Chemistry
|
May 2, 2024
Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2
Yunhang Guo, Hai Xue, Nan Hu, et al.
Journal of Medicinal Chemistry
|
August 6, 2019
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo, Ye Liu, Nan Hu, et al.
Page
of 10